Brief: Sandoz Signs Global License Agreement With Eirgenix To Commercialize Pertuzumab

Sandoz AG

12/11/2025 06:38

Nov 12 (Reuters) - SANDOZ GROUP AG SDZ.S:

SIGNS GLOBAL LICENSE AGREEMENT TO COMMERCIALIZE BREAST CANCER BIOSIMILAR PERTUZUMAB

UNDER TERMS OF AGREEMENT, SANDOZ HAS EXCLUSIVE WORLDWIDE COMMERCIAL RIGHTS TO A BIOSIMILAR OF PERTUZUMAB, EXCLUDING CERTAIN COUNTRIES IN ASIA

AGREEMENT WITH EIRGENIX INC

Source text: ID:nEQgbgp6a

Further company coverage: SDZ.S

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com ; +48 587785269;;))